Moody's Ratings (Moody's) said that R1 RCM, Inc.'s ("R1 RCM") announcement that it signed a definitive merger agreement to be acquired by affiliates of TowerBrook Capital Partners ("TowerBrook") and Clayton Dubilier & Rice ("CD&R") has no immediate impact to R1 RCM's negative outlook and ratings, in...
Moody's Investors Service ("Moody's") said that the announcement by R1 RCM, Inc.'s ("R1" or "the company") that an investor group led by New Mountain Capital L.L.C. ("New Mountain"), representing certain managed funds, is considering making an offer to acquire all outstanding shares of R1 is a credi...
Moody's Investors Service ("Moody's") downgraded the corporate family rating (CFR) of R1 RCM, Inc. ("R1") to Ba3 from Ba2 and its probability of default ("PDR") to Ba3-PD from Ba2-PD. At the same time, Moody's assigned a Ba3 rating to the company's newly proposed $500 million term loan B due 2029 an...
Moody's Investors Service ("Moody's") said that R1 RCM Inc.'s ("R1") announcement of the postponement of its quarterly 10-Q filing for the three and nine months ended 30 September 2023 and the restatement of its previously issued financial statements for the years ended December 31, 2022 and 2021 an...
Moody's Investors Service ("Moody's") affirmed the ratings at R1 RCM Inc. ("R1"), a provider of technology-driven healthcare revenue cycle management ("RCM") services, including its Ba2 corporate family rating ("CFR") and Ba2-PD probability of default ("PDR"). Additionally, Moody's affirmed the comp...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.